Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Extended-Release Tolterodine: Results From the Overactive Bladder Innovative Therapy Trial

Journal of Urology

Volumn 182, Issue 3, 2009, Pages 1055-1061

  Peters, Kenneth M ^a   MacDiarmid, Scott A ^c   Wooldridge, Leslie S ^b   Leong, Fah Che ^d   Shobeiri, S Abbas ^e   Rovner, Eric S ^f   Siegel, Steven W ^g   Tate, Susan B ^h   Jarnagin, Barry K ⁱ   Rosenblatt, Peter L ^j   Feagins, Brian A ^k  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b MERCY HEALTH PARTNERS   (United States)

^c Alliance Urology Specialists   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g Metro Urology   (United States)

^h UNIVERSITY OF LOUISVILLE   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j Boston Urogynecology Associates   (United States)

^k Dallas Center for Pelvic Medicine   (United States)

more..

Author keywords

electric stimulation therapy; overactive; tibial nerve; tolterodine; urge; urinary bladder; urinary incontinence

Indexed keywords

TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RELEASE; EXPERIMENTAL THERAPY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE STIMULATION; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TIBIAL NERVE; TREATMENT DURATION; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; TIBIAL NERVE; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 68149156396     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.05.045     Document Type: Article

References (23)

1. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 62 (2003) 28
2. Perfetto E.M., Prasun S., and Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Am J Manag Care 11 (2005) S150
3. Coyne K.S., Elinoff V., Gordon D.A., et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 62 (2008) 925
4. Bulmer P., and Abrams P. The unstable detrusor. Urol Int 72 (2004) 1
5. Dmochowski R., and Newman D. Impact of overactive bladder on women in the United States. Results of a national survey. Curr Med Res Opin 23 (2007) 65
6. Leng W.W., and Chancellor M.B. How sacral nerve stimulation neuromodulation works. Urol Clin North Am 32 (2005) 11
7. van der Pal F., Heesakkers J.P., and Bemelmans B.L. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol 16 (2006) 261
8. Starkman J.S., Wolter C.E., Scarpero H.M., et al. Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. Neurourol Urodyn 26 (2007) 29
9. Schmidt R.A., Jonas U., Oleson K.A., et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 162 (1999) 352
10. Kohli N., and Rosenblatt P.L. Neuromodulation techniques for the treatment of the overactive bladder. Clin Obstet Gynecol 45 (2002) 218
11. Govier F.E., Litwiller S., Nitti V., et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol 165 (2001) 1193
12. Sand P and Zinner N: What is urgency? Examining the clinical adequacy of the ICS definition of urgency. Presented at the International Continence Society Conference, Montreal, Canada, August 28-September 2, 2005; abstract 56.
13. Coyne K.S., Matza L.S., and Thompson C.L. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14 (2005) 849
14. Peters K.M., Killinger K.A., Ibrahim I.A., et al. The relationship between subjective and objective assessments of sacral neuromodulation effectivness in patients with urgency-frequency. Neurourol Urodyn 27 (2008) 775
15. McGuire E.J., Zhang S.C., Horwinski E.R., et al. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol 129 (1983) 78
16. Stoller M.L. Afferent nerve stimulation for pelvic floor dysfunction. Eur Urol 35 (1999) 16
17. Vandoninck V., Van Balken M.R., Finazzi Agro E., et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn 22 (2003) 17
18. van Balken M.R., Vandoninck V., Gisolf K.W., et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol 166 (2001) 914
19. Vandoninck V., van Balken M.R., Finazzi Agro E., et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn 22 (2003) 227
20. Kim S.W., Paick J.S., and Ku J.H. Percutaneous posterior tibial nerve stimulation in patients with chronic pelvic pain: a preliminary study. Urol Int 78 (2007) 58
21. Klingler H.C., Pycha A., Schmidbauer J., et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology 56 (2000) 766
22. Kaptchuk T.J., Stason W.B., Davis R.B., et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 332 (2006) 391
23. Peters K., Carrico D., and Burks F. Validation of a sham for percutaneous tibial nerve stimulation. Neurourol Urodyn 28 (2009) 58